A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients with Neutrophilic Skin Diseases
Volunteers with neutrophilic skin disease are needed to participate in a research study to assess the safety, tolerability, and activity of an investigational drug that is being developed as a potential treatment for plaque psoriasis, palmoplantar pustulosis, or hidradenitis suppurativa.
Eligible participants will be men and women diagnosed with one of these conditions and are not currently using a biologic agent to treat their skin disease. Participation requires 15 outpatient visits over the course of approximately 15 months. Financial compensation is provided to enrolled participants.
Condition | Skin Infections/Disorders, Psoriasis and Psoriatic Disorders |
---|---|
Clinical Study Identifier | TX147610 |
Last Modified on | 25 March 2021 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.